Trial Profile
A prospective, randomised, open label study to compare the efficacy, safety and tolerability of 17B estradiol/TMG CC [estradiol/trimegestone] 1mg and tibolone in postmenopausal women.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Estradiol/trimegestone (Primary) ; Tibolone (Primary)
- Indications Menopausal syndrome
- Focus Therapeutic Use
- Sponsors Pfizer; Wyeth
- 19 Nov 2010 Planned number of patients changed from 200 to 204.
- 19 Nov 2010 Status changed from active, no longer recruiting to completed.
- 14 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.